RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)

MLA

Feng Wen, et al. “RC48-ADC Combined with Tislelizumab as Neoadjuvant Treatment in Patients with HER2-Positive Locally Advanced Muscle-Invasive Urothelial Bladder Cancer: A Multi-Center Phase Ib/II Study (HOPE-03).” Frontiers in Oncology, vol. 13, Jan. 2024. EBSCOhost, https://doi.org/10.3389/fonc.2023.1233196.

APA

Feng Wen, Tianhai Lin, Peng Zhang, & Yali Shen. (2024). RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03). Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1233196

Chicago

Feng Wen, Tianhai Lin, Peng Zhang, and Yali Shen. 2024. “RC48-ADC Combined with Tislelizumab as Neoadjuvant Treatment in Patients with HER2-Positive Locally Advanced Muscle-Invasive Urothelial Bladder Cancer: A Multi-Center Phase Ib/II Study (HOPE-03).” Frontiers in Oncology 13 (January). doi:10.3389/fonc.2023.1233196.